Enterprise Value

156.2M

Cash

33.04M

Avg Qtr Burn

-5.542M

Short % of Float

12.40%

Insider Ownership

11.99%

Institutional Own.

9.05%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details
Genetic disorder, Rare genetic disease

Approved

Update

Elelyso® (taliglucerase alpha) Details
Genetic disorder, Rare genetic disease

Approved

Quarterly sales

PRX-115 Details
Chronic refractory gout

Phase 1

Data readout

Alidornase alfa (PRX-110) Details
Genetic disorder, Rare genetic disease, Cystic fibrosis

Failed

Discontinued

OPRX-106 Details
Inflammatory disease, Bowel disorder

Failed

Discontinued